Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Trial data shows potential for the treatment regimen to become the new standard of care for BRAF V600E-mutant metastatic colorectal cancer.
read more
Israel-based gummy supplements provider snaps up the Canadian CDMO Island Abbey in a deal worth over $20 million.
read more
Sage’s Board says the $469 million proposal “significantly undervalues Sage” and is not in the best interest of shareholders.
read more
Iclepertin, a once-daily oral treatment for cognitive impairment in schizophrenia, failed to best a placebo in a series of three trials.
read more
Calquence is the first and only BTK inhibitor approved for the first-line treatment of MCL in the U.S.
read more
The global pharmaceutical and nutraceutical excipient manufacturer has appointed Sven Abend as the company’s new CEO.
read more
Gilead looks to use the STAT6 pathway to develop an oral option for patients suffering from chronic inflammatory conditions.
read more
LNK International is recalling a batch of Kirkland branded cold and flu capsules after shipping potentially contaminated product.
read more
The star of the deal is Intra-Cellular's FDA-approved and potential blockbuster drug, Caplyta.
read more
Viking Therapeutics announced the initiation of a phase 2 clinical trial of the oral tablet formulation of its dual GLP-1/GIP receptor agonist, VK2735.
read more
The Denmark-based startup will focus on high-value oral alternatives to blockbuster injectable biologics.
read more
Denali revealed disappointing topline results from a phase 2/3 trial evaluating its eIF2B agonist in the treatment of amyotrophic lateral sclerosis.
read more
A simple dietary supplement may provide a new approach to boost CAR-T cell function, according to UPenn researchers.
read more
Products sold over the counter may contain undeclared tadalafil and sildenafil and could be harmful.
read more
With three out of four trials hitting primary endpoints, Axsome will submit its dextromethorphan/bupropion combo to the FDA for Alzheimer’s agitation.
read more